HOOKIPA Pharma Inc. HOOK
1.15 USD 0.00 (+0.00%)
Jul 17, 2026, 9:30 AM EDT
1.15 Day range 1.15
52-week range unavailable
- YTD
- +28.78%
- 1 year
- -19.01%
News
globenewswire.com HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase price Next-generation therapeutic cancer…
globenewswire.com HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA's HB-400 program and…
globenewswire.com HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
globenewswire.com HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A…
globenewswire.com HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A…
globenewswire.com Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
globenewswire.com HOOKIPA Pharma Inc - FORM 8 (OPD) NEW YORK and VIENNA, Austria, Jan. 08, 2025 (GLOBE NEWSWIRE) -- FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER Rules 8.1 and 8.2 of the Takeover Code (the “Code”) 1. KEY…
globenewswire.com HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation…
proactiveinvestors.co.uk Gilead backs proposed Poolbeg Pharma's proposed tie-up with HOOKIPA Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS), the largest shareholder in HOOKIPA Pharma, has thrown its backing behind the proposed merger with Poolbeg Pharma PLC (AIM:POLB). Gilead, which holds just…
globenewswire.com Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
globenewswire.com HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
globenewswire.com Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
globenewswire.com HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell…
globenewswire.com HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 Society of Immunotherapy of Cancer…
globenewswire.com HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service
globenewswire.com HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024 Preclinical proof-of-concept package to be presented at Industry Summit on RAS being…
zacks.com Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet The mean of analysts' price targets for HOOKIPA Pharma (HOOK) points to a 622.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among…
globenewswire.com HOOKIPA Pharma Announces Board of Directors Changes NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary…
globenewswire.com HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference NEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a company developing a new class of immunotherapeutics based on its proprietary…
globenewswire.com HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2024
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.
benzinga.com Earnings Scheduled For November 9, 2023 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday saw 132 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
benzinga.com Earnings Scheduled For August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.- benzinga.com Earnings Scheduled For May 11, 2023 Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its…
benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 149 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 93 stocks made new 52-week lows.
- benzinga.com Earnings Scheduled For March 15, 2023 Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.
- benzinga.com Stocks That Hit 52-Week Lows On Monday Monday saw 196 companies set new 52-week lows.
- benzinga.com Earnings Scheduled For November 14, 2022 Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 517 companies set new 52-week lows.
- benzinga.com Earnings Scheduled For August 11, 2022 Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
- benzinga.com Earnings Scheduled For May 16, 2022 Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
benzinga.com 68 Biggest Movers From Yesterday Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 41 Stocks Moving In Wednesday's Mid-Day Session Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi Here's a roundup of top developments in the biotech space over the last 24 hours.- benzinga.com 28 Stocks Moving in Wednesday's Pre-Market Session Gainers Guardion Health Sciences, Inc. (NASDAQ: GHSI) rose 46.4% to $0.4098 in pre-market trading after jumping around 48% on Tuesday. Guardion Health Sciences recently reported closing of $11…
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 209 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 615 stocks hit new 52-week lows.
- benzinga.com Stocks Hitting New 52-Week Lows Today On Monday morning, 60 companies achieved new lows for the year.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For November 12, 2021
- benzinga.com Earnings Scheduled For November 10, 2021 Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 155 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday morning, 282 companies set new 52-week lows.